Experimental cancer drug tested in patients out of options
NCT ID NCT06098651
Summary
This early-stage study tested a new drug called DCR-STAT3 in adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it in 26 participants. Researchers also looked for early signs that the drug might help shrink tumors or activate the immune system against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Next Oncology
Dallas, Texas, 75039, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.